TARS offering history
Every offering-related filing in Tarsus Pharmaceuticals, Inc.’s recent SEC record — registrations (announced capacity) kept separate from pricing documents (executed sales). Reviewed 646 filings back to Aug 7, 2020.
| Date | Filing | What it means | |
|---|---|---|---|
| Aug 6, 2026 | 8-K → | EXECUTED | Unregistered share sale disclosed (8-K item 3.02) |
| Aug 6, 2026 | 8-K → | EXECUTED | Unregistered share sale disclosed (8-K item 3.02) |
| Jul 8, 2026 | 8-K → | EXECUTED | Unregistered share sale disclosed (8-K item 3.02) |
| Mar 13, 2025 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Mar 12, 2025 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Mar 1, 2024 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Feb 29, 2024 | S-3ASR → | REGISTERED | Automatic shelf registration — effective immediately (large filers) |
| Feb 29, 2024 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Nov 21, 2023 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| Nov 9, 2023 | S-3 → | REGISTERED | S-3 registration — capacity to sell shares, not a sale yet |
| Aug 2, 2023 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Jul 31, 2023 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| May 4, 2022 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| May 3, 2022 | FWP → | MARKETING | Free-writing prospectus — offering being marketed |
| May 2, 2022 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Nov 5, 2021 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| Nov 1, 2021 | S-3 → | REGISTERED | S-3 registration — capacity to sell shares, not a sale yet |
| Oct 16, 2020 | 424B4 → | EXECUTED | Final prospectus — offering priced (typical for IPOs and marketed share deals) |
| Oct 15, 2020 | S-1MEF → | REGISTERED | S-1MEF registration — capacity to sell shares, not a sale yet |
| Oct 15, 2020 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| Oct 9, 2020 | S-1/A → | REGISTERED | S-1/A registration — capacity to sell shares, not a sale yet |
| Sep 25, 2020 | S-1 → | REGISTERED | S-1 registration — capacity to sell shares, not a sale yet |
Two honest limits. (1) A 424B takedown can price shares or notes— EDGAR’s metadata doesn’t say which, so open the document: large investment-grade filers use these mostly for bond deals (no dilution), small-caps mostly for shares. (2) At-the-market (ATM) programs sell shares gradually and individual sales are not separately filed — the visible footprint is the enabling shelf and its 424B5; actual ATM share counts surface later in the 10-Q/10-K share count. Educational information from public filings, not investment advice.
TARS offering FAQ
When did TARS last execute an offering?
Per SEC filings, Tarsus Pharmaceuticals, Inc.'s most recent priced offering document is a 8-K filed 2026-08-06. Note a 424B takedown can price shares or notes (debt) — the linked document says which.
When did TARS last announce or register an offering?
The most recent registration is a S-3ASR filed 2024-02-29. A registration is capacity to sell shares — not a sale.
Does an offering always mean dilution?
Registered direct offerings and shelf takedowns issue new shares and dilute existing holders. Resale registrations (424B3/B7) let existing holders sell and do not create new shares. Secondary sales by insiders also do not dilute. Each row here is labeled with what it is.